QURE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose that the design of uniQure's Pivotal Study was not fully approved by the FDA [1] - Defendants downplayed the likelihood that uniQure would have to delay its Biologics License Application (BLA) timeline to perform additional studies, despite purportedly successful results from the Pivotal Study [1] - As a result, the statements made by Defendants regarding the company's business, operations, and prospects lacked a reasonable basis [1] Group 2: Impact of FDA Disclosure - On November 3, 2025, uniQure disclosed that the FDA "currently no longer agrees" that data from the Phase I/II AMT-130 studies would be adequate to support a BLA submission [1] - The company admitted that the timing of any BLA submission for AMT-130 was now unclear, revealing the falsity of prior representations that AMT-130 was on a near-term path toward accelerated approval [1] - Following this disclosure, uniQure's ordinary share price fell by $33.40 per share, or more than 49%, from a close of $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1]